Text Size: a  |   a 

Pipeline Drug: Ontinua ER

October 1st, 2015

Osmotica Pharmaceutical Corp, a pharmaceutical corporation that specializes in developing therapeutics for treatment of CNS diseases, announced that the filing application for new drug Ontinua ER has been accepted by the FDA.


Ontinua ER (arbaclofen) can be classified as extended release tablets for alleviation of spasticity caused by Multiple Sclerosis. Spasticity could be classified as something as mild as muscle tightness or it could be painful spasms of the legs or arms. Treatment is needed to prevent the deterioration of the patient’s joints. The drug is to be taken twice a day by the patient.


“OntinuaTM ER given twice a day was shown to meet the co-primary endpoints of the Modified Ashworth Scale and the Clinical Global Impression of Change in the clinical study,” said Mark Stacy, MD, Vice Dean for Clinical Research, Duke University School of Medicine and head of the Osmotica’s Scientific Advisory Board. “OntinuaTM ER represents a great treatment option for MS patients with spasticity, and we look forward to bringing this therapy to patients.”

Source: http://www.businesswire.com/news/home/20150928006528/en/#.Vg2LB_lVhBc